Last reviewed · How we verify
Mk0476 Phase II Dose Finding Study -Allergic Rhinitis-
The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.
Details
| Lead sponsor | Organon and Co |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 945 |
| Start date | 2004-02 |
| Completion | 2004-03 |
Conditions
- Rhinitis Allergic
Interventions
- MK0476, montelukast sodium / Duration of Treatment: 2 Weeks
- Comparator: placebo / Duration of Treatment: 2 Weeks
Primary outcomes
- The change from baseline in the composite nasal symptoms score (average over the 2-week treatment period) in seasonal allergic rhinitis